“We are very pleased with the successful relationship we have built with AstraZeneca and their selection of a validated microRNA target for oncology indications,” said Neil W. Gibson, PhD, chief scientific officer of Regulus.

“In the last year, we have made significant progress in advancing our drug discovery efforts against the portfolio of AstraZeneca targets.  With the support of AstraZeneca’s drug development expertise and commitment to the RNA therapeutics field, we continue to harness our microRNA expertise to develop innovative, first-in-class treatment options for patients in need.”

In August 2012, Regulus and AstraZeneca formed a strategic alliance focused on three exclusive microRNA targets for cardiovascular and metabolic diseases and oncology, which includes Regulus’ program targeting microRNA-33 for the treatment of atherosclerosis.

Under the terms of the alliance, Regulus will lead preclinical development and, if successful, could receive preclinical milestone payments.  AstraZeneca will lead and fund the clinical development and commercialization of these programs.  In addition, Regulus could also receive clinical milestones based on the successful development of microRNA therapies in each target area.

Regulus is also eligible to receive significant launch and commercial milestone payments and royalties contingent on the successful commercialization of microRNA therapeutic products by AstraZeneca.

Date: October 28, 2013

Source: Regulus Therapeutics